Introduction
============

Drug use causes considerable harm because of premature death and disability as well as other adverse health effects. The United Nations Office on Drugs and Crime estimated that around 0.6% of the world population suffers from substance use disorders ([@B205]). Although opioids are considered the most harmful drugs for their addiction potential and negative consequences, cannabis use is a much larger problem when it comes to the number of users. Around 183 million "past-year" cannabis users were reported worldwide in 2015, which is 2.6 times higher than the cumulative number of "past-year" worldwide users of opioids, amphetamines and cocaine, making cannabis the most widely used illicit drug at a global level ([@B205]). Although worldwide cannabis use has remained stable (3.4% in 1998 versus 3.8% in 2015), the absolute number of cannabis users has increased because of the growing world population, especially in Africa and Asia ([@B205]). Legalization of marijuana for medical and recreational purposes might increase cannabis use even further ([@B102]). In addition to traditional marijuana use, the use of synthetic cannabinoids (i.e., designer drugs that mimic the physical and psychological effects of delta-9-tetrahydrocannabinol (THC), the primary active constituent in cannabis) is gaining considerable popularity. Since 2008, when the first synthetic cannabinoid (JWH-018) was detected in the market, at least 169 different synthetic cannabinoids have been discovered ([@B74]; [@B64]). The emergence of synthetic cannabinoids is becoming an increasing concern because of their undetermined addiction potential and adverse health effects ([@B70]; [@B224]; [@B54]; [@B231]).

Acute toxicity of traditional cannabis use is considered low ([@B158]); yet, long-term cannabis use is associated with serious adverse health effects which include lower birth weight of offspring (maternal cannabis smoking), diminished lifetime achievement, development of psychosis, depression or anxiety, symptoms of chronic bronchitis, motor vehicle accidents, and risk of cannabis addiction ([@B95]; [@B217]; [@B205]). Although the existence of cannabis addiction was disputed in the 1990s, current evidence predicts that around 1 in 10 cannabis users will develop cannabis addiction or dependence ([@B128]), which is currently defined as cannabis use disorder (CUD) in the fifth edition of the Diagnostic and Statistical Manual for Mental Disorders (5th ed.; DSM-5; [@B3]). CUD is characterized by high cannabis intake over longer periods of time, problems with controlling cannabis use, tolerance, withdrawal signs, craving and negative effects on personal, social and occupational activities (DSM-5).

The demand for CUD treatment is increasing dramatically. The European Monitoring Centre for Drugs and Drug Addiction reported a 50% increase in the number of first-time entrants for CUD treatment in 2011 ([@B63]). The increasing need for CUD treatment is thought to be driven by the increased availability of cannabis products containing higher concentrations of THC or synthetic cannabinoids ([@B82]). Regrettably, current CUD treatment protocols show modest effects only ([@B28]; [@B223]). Delineating risk factors involved in the initiation and maintenance of cannabis use therefore becomes increasingly important and critical for optimizing evidence-based prevention and treatment protocols.

Similarly to other drugs of abuse, cannabis use differs remarkably between males and females ([@B62]), indicating a different sensitivity to cannabinoid-induced effects in the two sexes ([@B53]; Figure [1](#F1){ref-type="fig"}). Although it remains uncertain which specific biological (i.e., sex) and socio-cultural (i.e., gender) factors affect cannabis use in humans, animal studies strongly suggest the involvement of sex ([@B73]) and anabolic-androgenic steroids (AAS) hormones ([@B198]) as important modulators of cannabinoid sensitivity. This review aims to describe the role of sex differences in cannabis use with reference to the modulating role of sex and AAS hormones (Figure [2](#F2){ref-type="fig"}) in cannabinoid sensitivity.

![Male to female ratios of lifetime cannabis use (CU) and progression toward cannabis use disorder (CUD) among students (15--16 years) and adults ([@B62]). Although males have a higher risk of developing CUD ([@B233]), progression toward CUD is faster in females ([@B115]).](fnbeh-12-00249-g001){#F1}

![Chemical structures of the main male and female sex hormones and the anabolic-androgenic steroid nandrolone. The strict chemical homology with a common core cyclic structure among natural and synthetic steroids accounts for the relatively high cross-reactivity displayed by sex steroids and AAS at receptor level. The only difference between testosterone and nandrolone (19-nortestosterone) is the methyl group (CH~3~) of nandrolone in position C19 instead of the hydrogen (H) of testosterone, which increases the anabolic activity of nandrolone and is at the basis of its use as a doping drug (see [@B29] and references enclosed).](fnbeh-12-00249-g002){#F2}

Risk Factors for Cannabis Use
=============================

As for other drugs of abuse, both genetic and environmental factors play a role in cannabis use and addiction ([@B1]; [@B212]). Twin studies estimate that the genetic contribution to cannabis use is between 17 and 67%, while the genetic contribution to cannabis addiction is much higher and ranges from 45 to 78% ([@B212]; [@B213]; [@B57]; [@B131]). Interestingly, the genetic contribution to the initiation of cannabis use increases with age ([@B57]) and is higher in males than in females ([@B207]). Although it is clear that genetics is an important risk factor in cannabis use and abuse, it has so far proved difficult to identify specific gene variants that alter cannabis sensitivity. At present, most genome-wide association studies (GWAS) failed to detect significant associations between cannabis use and genetic variants ([@B2]; [@B211]; [@B197]). However, using gene-based testing, four genes that are significantly associated with lifetime cannabis use have been recently identified, which include the neural cell adhesion molecule 1 (NCAM1), the cell adhesion molecule 2 (CADM2), the Short Coiled-Coil Protein (SCOC) and the potassium sodium-activated channel subfamily T member 2 (KCNT2) ([@B197]). Interestingly, NCAM1 has been associated with substance abuse ([@B86]) and is part of the NTAD gene cluster (NCAM1-TTC12-ANKK1-DRD2) which is linked to neurogenesis and dopaminergic signaling ([@B229]). In the most recent GWAS, single-nucleotide polymorphisms (SNPs) in novel antisense transcript RP11-206M11.7, solute carrier family 35 member G1, and the CUB and Sushi multiple domains 1 gene were significantly associated with cannabis dependence ([@B192]). However, whether or not these genes contribute to altered cannabinoid action remains unclear. Next to genetic variation, epigenetic-dependent changes in gene expression might contribute to altered cannabinoid sensitivity. Interestingly, a recent study reported increased DNA methylation of the NCAM1 gene in cannabis users compared to control subjects ([@B87]).

The vulnerability to initiation of cannabis use and CUD development appears heritable. Yet, numerous social and environmental factors (e.g., age of cannabis use initiation, peer drug use, availability of drugs, low socio-economic status, experience of childhood sexual abuse, cigarette smoking or alcohol drinking during early adolescence) and the presence of pre/comorbid psychopathology (e.g., mood disorders, ADHD, psychosis) are thought to enhance the risk of transitioning from initiation of cannabis use to CUD (reviewed in [@B46]). Personality/biological traits, such as impulsivity, schizotypy and sensation-seeking, are also positively correlated with the initiation of cannabis use in adolescents and young adults ([@B98]; [@B156]).

As for other drugs of abuse, the prevalence of cannabis use differs remarkably between males and females (Figure [1](#F1){ref-type="fig"}; [@B62]) and sex is considered an important risk factor for cannabis use ([@B43]). Among 15--16-years-old students, lifetime cannabis use is higher in males than in females and the male to female ratio (M/F) of lifetime cannabis use increases even further among all adults (M/F: 1.25--4.0) ([@B62]). Although males have a higher risk of developing CUD ([@B233]), progression toward CUD is slightly faster in females than in males ([@B115]; [@B64]). Males also show different cannabis use patterns as compared to females and appear to use cannabis more frequently and at higher amounts ([@B51]). However, a faster progression to problematic cannabis use ([@B44]) and more severe withdrawal symptoms ([@B124]) could explain why women typically show greater propensity to relapse to drug use than men ([@B17]; [@B71]).

The fact that differences in cannabis use between males and females vary across countries suggests an influence of environmental (i.e., socio-cultural) factors. However, animal studies clearly indicate that biological factors, such as sex hormones and chromosomes, are significant modulators of drug sensitivity ([@B175]; [@B138]). In keeping with this, gender-tailored detoxification treatments and relapse prevention strategies for patients with CUD are increasingly requested ([@B69]).

Sex Steroid Hormones
====================

Sex differences arise because of differences in sex chromosomes. The presence of the sex-determining region of Y (Sry) gene on the Y chromosome induces testicular development and consequently the production of testosterone ([@B173]). Testosterone and its derivative dihydrotestosterone (DHT) are responsible for the development of the male phenotype. Absence of the Sry gene leads to the development of ovaries that produce estradiol and progesterone. Estrogens, progesterone and testosterone have a strong impact on sexual differentiation, maturation and adult sexual behavior ([@B8]; [@B141]; [@B221]; [@B144]; [@B104]; [@B154]; [@B15]; [@B6]; [@B155]). The presence of sex hormones during development gives rise to various organizational differences in the male and female brain, which ultimately affect reproductive and non-reproductive behavior ([@B13]).

Sex hormones are synthesized by conversion of cholesterol into pregnenolone, which is the precursor of all steroid hormones ([@B96]). Interestingly, pregnenolone protects the brain from cannabinoid type-1 receptor (CB1R) overactivation, by acting as a potent endogenous allosteric inhibitor of CB1Rs ([@B206]), and prevents cannabinoid-induced psychosis in mice ([@B30]). Sex hormones can be divided into three main subtypes with distinct molecular functions and sexually dimorphic expression and distribution: androgens (e.g., testosterone, dehydroepiandrosterone, androstenedione), estrogens (e.g., 17-alpha and 17-beta estradiol, estrone, estriol) and progestogens (e.g., progesterone, allopregnanolone, pregnenolone) (Figure [2](#F2){ref-type="fig"}). Sex hormones are produced by the gonads in response to the stimulating activity of the pituitary gonadotropins whose release is, in turn, under the control of the hypothalamic gonadotropin releasing hormone (GnRH). At the central level, several neurotransmitters are able to modify the release of GnRH, including norepinephrine, dopamine, serotonin, gamma-aminobutyric acid (GABA) and glutamate ([@B183]). Cannabinoids were found to significantly modulate the activity of the hypothalamic-pituitary-gonadal (HPG) and -adrenal (HPA) axes ([@B27]) and their interactions ([@B112]). Interestingly, sex hormones influence the action of cannabinoids on these axes ([@B127]) suggesting bidirectional interactions between sex hormones and the endocannabinoid system (Table [1](#T1){ref-type="table"}).

###### 

Main findings from representative studies investigating the interaction between the endocannabinoid system and the sex or ASS hormones.

  Main finding(s)                                                                                                                                         Reference
  ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------
  THC accumulates in testes in rats                                                                                                                       [@B101]
  Chronic consumption of cannabis significantly lowers plasma testosterone levels in humans                                                               [@B117]
  THC exerts its influence on rodent sexual behavior by exerting centrally mediated effects                                                               [@B89]
  Acute administration of THC inhibits luteinizing hormone (LH) in males and females across a variety of mammalian species (from mice to monkeys)         [@B162]; [@B37]; [@B10]; [@B20]; [@B38]; [@B52]
  Cannabinoids suppress GnRH secretion by modulating the activity of neurotransmitters involved in the regulation of GnRH secretion                       [@B196]; [@B157]
  Brain CB1R expression significantly differs between males and females and displays a strong sex hormone-dependent modulation in female rats             Rodríguez de Fonseca et al., 1994
  The content of the endocannabinoid AEA and 2-AG significantly differs between males and females and is affected by hormonal cycling in female rats      [@B88]; [@B26]
  Estrogen inhibits FAAH *in vitro* and *in vivo*                                                                                                         [@B132]; [@B220]
  Sex hormones (progesterone), CB1Rs and D1Rs interact to regulate female rodents' sexual behavior, and possibly, other motivated behaviors               [@B136]
  AEA suppresses LH and testosterone levels in WT, but not CB1R-KO mice                                                                                   [@B225]
  The inhibitory effects of cannabinoids on HPG axis function are reversed by estrogen                                                                    [@B191]
  Immortalized GnRH neurons *in vitro* are capable of synthesizing endocannabinoids which exert immediate negative feedback control over GnRH secretion   [@B84]
  The anabolic steroid nandrolone blocks THC-induced CPP and increases the somatic manifestations of THC precipitated withdrawal                          [@B35]
  The ovarian hormones significantly affect cannabinoid seeking and taking behavior in rats                                                               [@B76], [@B77]
  Systemic administration of the CB1R antagonist AM251 blocks the orexigenic effect of testosterone                                                       [@B24]
  Testosterone in adult males and estradiol in adult females modulate THC metabolism                                                                      [@B47]
  Nandrolone modifies cannabinoid self-administration and brain CB1R density and function                                                                 [@B198]

2-AG, 2-arachidonoylglycerol; AEA, anandamide; AAS, androgenic anabolic steroids; CB1R, cannabinoid sub-type 1 receptor; CPP, conditioned place preference; D1R, dopamine sub-type 1 receptor; FAAH, fatty acid amide hydrolase; GnRH, Gonadotropin Releasing Hormone; HPG, hypothalamic--pituitary--gonadal; KO, knock-out; LH, luteinizing hormone; WT, wild type.

The main molecular targets of sex hormones are members of the nuclear hormone receptor family, which areligand-activated transcription factors involved in the regulation of gene expression ([@B135]). Testosterone, estrogen and progesterone target the androgen receptors (ARα and ARβ), the estrogen receptors (ERα and ERβ) and the progesterone receptor, respectively, although considerable receptor "*promiscuity*" might exist in each case. Nuclear receptors are ubiquitously expressed in the central nervous system (CNS), including areas associated with reward and addiction ([@B23]). Besides transcriptional effects, sex hormones are also reported to have fast non-genomic actions by modulating the activity of G protein-coupled receptors (GPRCs), ion channels and signaling proteins ([@B194]).

Sex hormones cause permanent organizational sex differences that are fixed during early development but they also maintain certain sex differences during the adult phase as long as these hormones are present, i.e., induce activational effects ([@B140]). For example, gonadectomy in adulthood completely suppresses sexual behavior in males and receptive and proceptive behaviors in females, all effects being reverted by exogenous hormonal replacement ([@B150]; [@B151]; [@B107]). When released, sex hormones are also able to deeply influence the organization and activity of one of the most important target organs of hormonal action, which is the brain ([@B8]; [@B142]). Gonadal hormones thus provide a biological basis for sex differences in endocannabinoid-related behaviors and are expected to contribute to the sexual dimorphic actions of cannabinoids ([@B48]; [@B49]).

Sex Differences in the Endocannabinoid System
=============================================

The endocannabinoid system is an evolutionary conserved signaling system that modulates multiple functions and consists of cannabinoid receptors, endogenous ligands (i.e., endocannabinoids) and several enzymes involved in the synthesis and degradation of endocannabinoids. The receptors and endogenous ligands of the endocannabinoid system were discovered in the late '80s and early '90s, respectively. CB1Rs are highly expressed in the brain ([@B204]; [@B83]; [@B103]) and are considered the main type of receptor mediating cannabinoid signaling in response to exposure to THC ([@B152]). CB1Rs are also highly expressed in fat tissue which might explain their role in energy homeostasis regulation, while cannabinoid type-2 receptors (CB2Rs) are predominantly expressed in cells of the immune system ([@B209]). CB1Rs and CB2Rs are GPCR and can be activated by THC or endogenous cannabinoid ligands like anandamide (AEA) and 2-arachidonylglycerol (2-AG) ([@B143]). Activation of cannabinoid receptors results in the modulation of several signals, including inhibition of adenylate cyclase, activation of the MAPK pathway, stimulation of inwardly rectifying K^+^ channels, and inhibition of voltage-activated Ca^2+^ channels. Ultimately, cannabinoid receptor activation modulates the activity of most neurotransmitter systems, including GABA, glutamate, dopamine, and serotonin ([@B208]). The tonic 2-AG signaling at inhibitory inputs onto dopamine neurons has been shown to differ between sexes ([@B146]), supporting the notion that there are quantitative differences in the endocannabinoid system in males and females which likely contribute to altered cannabinoid sensitivity. Noteworthy, several sex differences in the endocannabinoid system are related to changes in steroid hormone levels and activity.

Sex hormones can affect the activity of several neurotransmitters in the CNS, including the endocannabinoid functioning ([@B161]; [@B153]), and significant sex-dependent differences in CB1R density and function have been described (reviewed in [@B5]). In a pioneering work, [@B177] investigated the expression of brain CB1Rs in male and female rats under different hormonal conditions and reported higher CB1R binding in males than females in almost all the brain areas investigated (i.e., striatum, limbic forebrain, and mesencephalon). Notably, CB1R binding in males was not affected by gonadectomy and/or testosterone replacement, while in females a strong sex hormone-dependent modulation of CB1R expression was observed, with ovariectomy increasing CB1R affinity in the striatum and decreasing CB1R density in the limbic forebrain ([@B177]). [@B88] found that males have higher levels of CB1R-mRNA transcripts than females in the anterior pituitary gland but that, in females, CB1R-mRNA transcripts fluctuate during the different phases of the ovarian cycle with the highest expression on the second day of diestrus and the lowest expression on estrus. Based on these findings it was suggested that higher levels of estrogen in the anterior pituitary gland could serve to inhibit CB1R expression, reducing the inhibitory endocannabinoid tone within the HPG axis around the time of ovulation ([@B127]). More recently, [@B34] found that CB1R density was significantly lower in the prefrontal cortex (PFC) and amygdala of cycling females compared to males and ovariectomized (OVX) females, and that administration of estradiol to OVX markedly reduced the density of CB1Rs to the levels observed in cycling females. In addition, OVX females displayed higher CB1R function in the cingulate cortex compared to intact and OVX + estradiol females. Interestingly, sex and estradiol also affected motor activity, social behavior and sensorimotor gating ([@B34]), which are behaviors sensitive to the effects of different classes of drugs of abuse, in line with the idea that females can represent a more vulnerable phenotype (at neurochemical and behavioral level) than male rats in developing addiction-like behaviors. In addition, estradiol time-dependently modulates CB1R binding in brain structures that mediate nociception and locomotor activity ([@B219]).

Besides impacting on CB1R expression, sex hormones regulate the levels of endocannabinoids. [@B26], for example, measured the levels of AEA and 2-AG in several brain areas (i.e., pituitary gland, hypothalamus, thalamus, striatum, midbrain, hippocampus, and cerebellum) in male rats and in females at five different time points along the estrous cycle. They found that AEA content was higher in females than males in both the anterior pituitary gland and hypothalamus ([@B26]). With the exception of the cerebellum, all brain regions examined revealed significant differences along the estrous cycle in the level of at least one endocannabinoid, with changes occurring predominantly within the 36-h time period surrounding ovulation and behavioral estrus. In general, studies on the regulatory role of sex hormones on the endocannabinoid system failed to provide a clear and linear relationship between the two, and rather showed that these relations are quite complex and depend largely on the specific aspect considered (i.e., receptor affinity or density), the specific endocannabinoid (i.e., AEA or 2-AG) or the brain area investigated ([@B91]; [@B90]). The interpretation of these findings is further complicated by the fact that (i) all studies performed behavioral testing and/or tissue and serum collection at different time points after gonadectomy, (ii) animals were of different strains and tested at different ages (although they were adult in all studies), and that (iii) animals were kept under hormonal replacement regimen for different periods of time (1 day--3 weeks) before testing. However, the following findings are consistent among studies: (i) higher density of CB1Rs in male hypothalamus and limbic areas coupled, in general, with lower levels of endocannabinoids; (ii) there are significant differences along the hormonal cycle of females, with major changes occurring in the expression of CB1Rs in pituitary gland, hypothalamus and midbrain limbic structures when passing from diestrus to proestrus and behavioral estrus.

Sex steroids, like estrogens, can also regulate the activity of the endocannabinoid metabolizing enzymes. Fatty Acid Amide Hydrolase (FAAH) is the main enzyme involved in the degradation of AEA ([@B169]). The promoter region of the FAAH gene contains an estrogen binding response element, and translocation of the estrogen receptor to the nucleus results in repression of FAAH transcription *in vitro* ([@B220]) and *in vivo* ([@B132]). Ovariectomy prevents the estrogen-induced down-regulation of FAAH expression, and both progesterone and estrogen reduce basal levels of FAAH ([@B132]). The impact of estrogen-mediated regulation of FAAH activity at behavioral and neurochemical level is still under investigation ([@B100]).

In humans, plasma AEA levels fluctuate across the menstrual cycle, with a peak at ovulation and the lowest plasma AEA levels observed during the late luteal phase ([@B61]). In addition, significant positive correlations exist between plasma levels of AEA and plasma levels of estradiol, luteinizing (LH) and follicle-stimulating hormone (FSH) levels ([@B61]). More recently, brain imaging studies revealed sex differences in the endocannabinoid system. By using positron emission tomography (PET) and the CB1R-selective radioligand \[(11)C\]OMAR it was shown that CB1R availability is higher in healthy females than in males ([@B160]; [@B163]). In addition, it was reported that anandamide levels are lower in females than males ([@B160]). Another study combined PET with the CB1R-selective radioligand \[18F\]MK-9470 to examine CB1R binding in healthy men and women ([@B210]). In this study, CB1R binding was higher in males than in females in all the brain areas investigated and strongly increased with aging in females, suggesting that age-dependent changes in the levels of sex hormones can control CB1R binding in females ([@B210]).

While some of the sexual dimorphisms in the brain endocannabinoid system might be permanent, cannabinoid sensitivity is not fixed and can be acutely modulated by hormone-dependent fluctuations of CB1R density, levels of endocannabinoids and of endocannabinoid metabolizing enzymes. Collectively, the hormone-driven sexual dimorphic endocannabinoid system provides a biological basis for sex differences in endocannabinoid-related behaviors, including reward-related behavior ([@B73]; [@B81]).

Sex Differences in Cannabinoid Action
=====================================

Numerous studies show sex differences in functions in which the endocannabinoid system is involved, which span from regulation of motivated behaviors, like sex activity ([@B91]; [@B127]; [@B4]) and food intake ([@B68]), to locomotor and exploratory activity ([@B48]; [@B47]), nociception ([@B203]; [@B47]), working memory ([@B50]), anxiety ([@B216]; [@B25]) and vulnerability to develop addictive disorders ([@B75]; [@B139]; [@B16]). Endocannabinoids are also directly involved in the anxiolytic effects of estrogen; in turn, estrogen may elicit changes in emotional behavior through an endocannabinoid mechanism ([@B100]).

Sexual maturation takes place under hormonal control during puberty and adolescence. Due to the deep changes occurring during these periods of life, individuals of both sexes are particularly (although differentially) sensitive to many stimuli, vulnerable toward the development of psychopathological conditions and more prone to abuse drugs, including cannabis ([@B226]; [@B193]; [@B218]). Exposure to cannabinoids during critical developmental periods alters several functions in adult animals ([@B187]; [@B179]), including working ([@B188]; [@B164]) and spatial memory ([@B180]), sensorimotor gating ([@B188]), anxiety and anxiolytic-like responses ([@B21]; [@B164]; [@B215]), anhedonia, depressive-like states ([@B188]; [@B181]) and sexual behavior ([@B36]). Long-term alterations induced by cannabinoids in the developing organism are well known ([@B94]; [@B159]; [@B172]; [@B214]; [@B195]; [@B60]; [@B176]; [@B179]; [@B145]) and recent reports are pointing out epigenetic mechanisms underlying cannabis action ([@B200], [@B201]; [@B174]). Yet, researchers started only recently to unravel sexually dimorphic long-term effects of early cannabinoid exposure on behavior, cognition and emotional states ([@B216]; [@B123]; [@B114],[@B113]).

For instance, the ability of sex hormones to affect cannabinoid self-administration was established only recently. Such a delay is probably due to the fact that human cannabis use is extremely difficult to model in laboratory animals ([@B166]) and that the development of reliable protocols of cannabinoid self-administration in mice ([@B137]), rats ([@B72]) and monkeys ([@B108]) has taken long time and efforts. Importantly, these models made it possible to investigate factors that modulate spontaneous cannabinoid intake in animals, including strain ([@B55]) and sex ([@B76], [@B77]). Notably, female rats are able to discriminate THC from vehicle at a lower dose and faster rate than male rats ([@B227]), although no significant sex differences were observed in the cannabinoid place preference test ([@B99]). Moreover, ovarian hormones were identified as important modulators of cannabinoid self-administration, since bilateral ovariectomy significantly reduced drug-taking and drug-seeking in female rats ([@B76], [@B77]). Unfortunately, which specific sex hormone is able to finely modulate cannabinoid intake is still uncertain, highlighting the need for studies that combine gonadectomy with hormone replacement.

The effects of hormonal fluctuation during the menstrual cycle on the responses to drugs of abuse have been consistently investigated ([@B202]; [@B31]; [@B222]). Yet, the influence of sex hormones and menstrual cycle on the subjective and objective effects of marijuana has only been occasionally studied in female smokers. For example, [@B93] found no effect of the specific phase of the menstrual cycle on marijuana intake, a finding consistent with the negative results reported by [@B125] which monitored cannabis-induced changes in pulse rate and mood in women during the follicular, ovulatory and luteal phases of the cycle. These earlier studies, however, failed to detect strong hormonal-dependent effects of marijuana intake along the menstrual cycle, and more controlled studies are needed before reaching any definitive conclusion on hormonal influences on cannabinoid use and sensitivity.

(Endo)Cannabinoids, Sex Hormones and Dopamine
=============================================

Sex hormones have been found to be important modulators of several drugs of abuse ([@B130]; [@B33]; [@B76], [@B71]; [@B129]; [@B32]; [@B199]). Estradiol and progesterone rapidly induce changes in dopaminergic signaling within the dorsal striatum and nucleus accumbens of female rats ([@B14]), effects that are important for the regulation of normal physiological states and relevant reproductive behaviors ([@B230]). While the enhancing effect of ovarian hormones on drug craving has been traditionally attributed to estrogens (even in view of their ability to elicit direct dopamine release in the brain), it was suggested that progesterone, rather than estradiol, is responsible for the reducing effect on drug-seeking behavior ([@B79]; [@B78]; [@B32]).

As discussed above, brain CB1R distribution, synthesis of endogenous cannabinoids and activity of enzymes involved in cannabinoid metabolism (turnover) are significantly affected by sex hormones. At systems level, hormone-dependent differences and fluctuations in cannabinoid function may directly affect the activity of brain neurotransmitters and structures involved in cognitive and emotional aspects of motivated behaviors ([@B190]; [@B18]; [@B105]; [@B184]; [@B92]; [@B39]; [@B56]; [@B19]), like feeding ([@B148]; [@B12]; [@B80]; [@B41]; [@B42]) and sexual behavior ([@B170]; [@B171]; [@B186], [@B185]) as well as psychopathological states ([@B58]; [@B133]) and addiction-like behaviors ([@B65], [@B66]). Such a modulation can happen (i) by a direct interaction of the cannabinoid system with the mesolimbic dopaminergic system, the core component of the neurobiological substrates at the basis of motivated behavior ([@B85]; [@B67]; [@B122]; [@B232]; [@B147]; [@B165]; [@B22]; [@B134]), or (ii) by indirect actions in limbic areas (e.g., hippocampus, amygdala, PFC) strictly interconnected with mesolimbic dopaminergic neurons through (mainly) glutamatergic projections to the ventral tegmental area and nucleus accumbens ([@B121]; [@B120]). Sex hormones can modulate cannabinoid influence on motivated behaviors and stress responses by acting also at the level of several hypothalamic nuclei ([@B45]).

The leading hypothesis that sex steroids and (endo)cannabinoid actions can converge on the dopaminergic mesolimbic system to regulate important motivational aspects in a sexually dimorphic manner deserves further confirmation. To date, it explains interactions of cannabinoids and sex hormones only at the level of specific brain systems, while most of the information at molecular and genetic/epigenetic level are still missing, although initial efforts in this direction have begun to fill the gap (see for example [@B136]; [@B84]; [@B200], [@B201]; [@B174]; [@B178]). Furthermore, this hypothesis takes into account almost exclusively the cannabinoid effects mediated by central CB1Rs, but CB2Rs may also play a part through their actions on brain dopamine systems ([@B126]). The importance of sex hormones in modulating drug sensitivity is further supported by studies that have shown a clear association between exposure to synthetic male steroids and drug sensitivity.

Anabolic-Androgenic Steroids and Cannabinoid Action
===================================================

Anabolic-androgenic steroids are synthetic derivatives of the male hormone testosterone and are used therapeutically for the treatment of various diseases including hypogonadism, angioedema, anemia, osteoporosis, and muscle wasting ([@B11]). Non-medical use of AAS is often observed among professional and non-professional athletes in order to improve physical appearance and enhance performance ([@B182]). Global lifetime prevalence rate of non-medical AAS use is estimated to be 3.3% ([@B182]). AAS doses used for non-medical purposes are typically much higher (10--100×) than doses for medical use and are associated with several physical and psychological side effects ([@B97]). Physical side effects that have been observed after use of AAS include infertility, baldness, breast development, severe acne, high blood pressure, blood clots, heart attack, and stroke ([@B97]). Possible psychological consequences of AAS use are increased aggression, anxiety, and depression ([@B97]). Clinical and epidemiological data show that AAS are often co-abused with addictive substances, including cannabis ([@B59]; [@B9]; [@B111]). Several reasons might explain why polypharmacy occurs in more than 95% AAS users ([@B167]). First, AAS users are known to take other drugs to counteract adverse side but they might also have a higher sensitivity toward substance abuse. Alternatively, AAS might have direct effects on various components of the brain reward system which alters the sensitivity of users toward other drugs of abuse.

Use of high doses of AAS can lead to addiction, which makes it conceivable that AAS are able to modulate the brain reward system ([@B110]). Although part of the rewarding effects of AAS might be derived from their effects on physical appearance, animal studies have shown that testosterone and other AAS can induce conditioned place preference in a dopamine receptor-dependent manner ([@B7]; [@B189]; [@B168]) and increase self-administration behavior ([@B40]; [@B228]). In addition to their effects on reward-related behavior, AAS cause molecular and neurochemical changes in the dopaminergic, serotonergic and opioid neurotransmitter systems ([@B106]; [@B116]; [@B234]) and alter the behavioral effects of different types of drugs ([@B118]; [@B119]; [@B109]).

Studies investigating the effects of AAS exposure on cannabinoid sensitivity are scarce at present. It was shown that testosterone significantly reduces THC-induced locomotor suppression or catalepsy in gonadectomized males ([@B48]; [@B47]) and that chronic exposure to nandrolone, a derivative of testosterone also known as 19-nortestosterone (Figure [2](#F2){ref-type="fig"}), blocked THC-induced conditioned place preference in rats ([@B35]). Further, we recently reported that chronic treatment of rats with nandrolone does not alter CB1R levels or function in several reward-related brain areas. However, when chronic nandrolone treatment is followed by cannabinoid self-administration, we observed a strong decrease in CB1R function in the hippocampus and a significant increase in cannabinoid intake ([@B198]). Given the profound effects that AAS have on various aspects of the molecular machinery of the brain reward system, it might come as no surprise that AAS also interfere with the rewarding properties of drugs of abuse, including cannabinoids.

Altogether, studies available so far suggest that AAS can have a repressing effect on the brain reward system, a notion that is strengthened by the observation that AAS reduce drug-induced neurochemical and behavioral effects of amphetamine, MDMA, THC, and cocaine, and increase voluntary alcohol and cannabinoid drug intake ([@B149]). The hypothesized AAS-induced suppression of the reward system might result in the use of higher doses of drugs, which is associated with a higher addiction risk. It would be intriguing to find out to what extent blockade of steroid hormone activity contributes to prevent the repressive effect of these hormones in the reward system. Further studies are needed also to assess whether or not AAS can act as gateway drugs and lead to CUD and to better understand how they can impinge upon the endocannabinoid signaling within the brain.

Conclusion
==========

Cannabis is the most commonly used illicit drug worldwide and its use is associated with multiple adverse health effect including the risk of addiction. Identifying factors involved in cannabis use and abuse is critical for optimizing evidence-based prevention and treatment protocols. Similarly to other drugs of abuse, the prevalence of cannabis use and addiction differs between males and females, suggesting that sex is an important modulator of cannabinoid sensitivity. Accumulating evidence shows that the endocannabinoid system is sexually dimorphic and that sex hormones play a key role. Hormone-driven differentiation of the endocannabinoid system seems to provide a biological basis for sex differences in endocannabinoid-related behaviors, including reward-related behaviors. While sex differences in cannabinoid action are being increasingly studied in animals, controlled human studies are still limited. The endocannabinoid system is, for its intrinsic characteristics, a privileged target of the actions of both sex and anabolic-androgenic steroid hormones at different levels and, in turn, it can modulate the activity of sex hormones (Table [1](#T1){ref-type="table"}). The observation that exposure to AAS causes dysfunction of the brain reward pathway in rats points to a potential risk factor for initiation of cannabis use, maintenance of regular use and development of CUD. The cross talk between endocannabinoid signaling and steroid hormones can occur differently in males and females, and many questions about underlying mechanisms remain unanswered, demanding further research in the field in an attempt to elucidate the basis of the sex differences often observed in cannabinoid sensitivity.
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